Legendre A.-S.,Observatoire du medicament |
Le Monnier S.,Center hospitalier intercommunal Eure Seine |
Chamouni P.,Center Regional Of Traitement Of Lhemophilie |
Damais A.,Pierre Mendes-France University |
And 9 more authors.
Transfusion Clinique et Biologique | Year: 2012
Purpose of the study: The établissement français du sang (EFS) distributes two types of platelet concentrates: using a single donor in aphaeresis platelet concentrate (SDAP), versus pooled platelet concentrates (PPC). A retrospective study performed by the Blood Derivatives Group at Observatory for Drugs, Medical Devices and Therapeutic Innovations (OMEDIT), in collaboration with EFS and haemovigilance correspondents from eight regional health care establishments, has analyzed platelet concentrates prescriptions and the position of the prescribers concerning PPC supply. Material and methods: Between the 2nd and 6th June 2008, 151 platelet concentrates were supplied by ESF. Data were collected for 144 platelet concentrates and in 83 transfused patients with an average age of 50. years. During this study, 33 PPC (23%) and 111 SDAP (77%) were supplied. Results: With regards to the 111 SDAP, the supply of PPC was refused in 47 cases (42%), accepted in 18 cases (16%) and unknown for 46 cases (42%). A total of 51 PPC could be supplied during this period, which represented 35% of platelet concentrates prescriptions. The rate of platelets before transfusion was known for 121 platelet concentrates, the median was 32G·L-1 for SDAP and 44G·L-1 for PPC. Conclusion: More frequent PPC use, with comparable therapeutic efficacy, could be interesting in a context of increasing platelet concentrates consumption in health care establishments. Moreover, prescribers did not seem to be against the idea. An information pamphlet on platelet concentrates was drafted and distributed to prescribers in order to promote the prescription of PPC. A second assessment is planned to measure the impact of this communication. © 2012 Elsevier Masson SAS. Source
Health traceability of implantable medical devices: Assessment of organizations in health facilities of Ile-de-France [Tracabilite sanitaire des dispositifs medicaux implantables : etat des lieux des organisations au sein des etablissements d'Ile-de-France]
Chan Hew Wai A.,Observatoire du medicament |
Moutel E.,Observatoire du medicament |
Borel C.,Observatoire du medicament |
Ait Aissa T.,Observatoire du medicament |
And 2 more authors.
Pharmacien Hospitalier et Clinicien | Year: 2016
Health traceability of implantable medical devices (IMD) aims at providing an exhaustive list of patients, who might be concerned by IMD recall. The purpose of this analysis is to make an up-to-date regional assessment of IMD traceability. Method. A survey analyzing health traceability of IMDs was carried out in 2013. Licensed professionals in medicine, in surgery and/or in obstetrics were interviewed in health facilities (HF) of Ile-de-France. Results. Out of the 161 hospitals contributing to the survey, the majority (62%) has a standardized and in use procedure of traceability implementation approved by the director (legal request). Recording the IMD's serial number by hospital pharmacy is not systematic and the use of barcodes readers remains low. Furthermore, clinical indications of expensive IMD implantation (IMD not included in the diagnosis-related groups) are scarce in health traceability database (28% of the HF). Discussion/conclusion. Hence, the IMD supply chain security is not yet totally guaranteed in HF of Ile-de-France. The next steps to be taken will involve the reorganization of some flows between hospital pharmacy and operating rooms, the improvement of IMD supply chain computerization and the incorporation of these conclusions in a quality and safety improvement policy endorsed by the management of each HF. © 2016 Published by Elsevier Masson SAS. Source